Publications
461 publications
- Date
- Relevance
-
Dolutegravir (Tivicay) for the indication infection with HIV-1
The WAR has approved a pharmacotherapeutic report for the medicine dolutegravir (Tivicay). In determining its therapeutic value, ...
-
Dike-Reeve of the health care polder
-
Sofosbuvir (Sovaldi) for the indication chronic hepatitis C in adult patients
Sofosbuvir for the treatment of chronic hepatitis C in adult patients has added therapeutical value in comparison to relevant ...
-
Macitentan (Opsumit) for the indication pulmonary arterial hypertension WHO class II to III
The WAR has approved a pharmacotherapeutic report for the medicine macitentan (OpsumitĀ®; an endothelin-1-receptor antagonist). In ...
-
Canagliflozin (Invokana) for the treatment of adults with 'type 2 diabetes mellitus'
The WAR has approved a pharmacotherapeutic report for the medicine canagliflozin (Invokana) in film-coated tablets with 100 ...
-
Delta-9-tetrahydrocannabinol and cannabidiol (Sativex) with patients with moderate to severe spasticity due to multiple sclerosis
The WAR has approved a pharmacotherapeutic report for the medicine delta-9-tetrahydrocannabinol and cannabidiol (Sativex) spray ...
-
Herpes zoster vaccine (Zostavax) for the prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia
The WAR reached the follow conclusions: Zostavax has an added therapeutic value in comparison with placebo for the prevention of ...
-
Alhydran (BAP Medical BV) hydrating creams for burns, radiodermatitis and hand-foot syndrome
Alhydran (or other hydrating (scar) creams) does not comply with established medical science and medical practice and is ...
-
Deep Brain Stimulation in patients with therapy-resistant obsessive-compulsive disorder
In the Netherlands this treatment is combined with cognitive behavioural therapy. This report is a summary of recommendations by ...
-
Diabetes Package Scan
In a package scan we analyse the adequacy and accessibility of the package of insured care for a particular disease. Does the ...